Focused On-demand Library for Probable ATP-dependent RNA helicase DDX60

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We employ our advanced, specialised process to create targeted libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q8IY21

UPID:

DDX60_HUMAN

Alternative names:

DEAD box protein 60

Alternative UPACC:

Q8IY21; Q6PK35; Q9NVE3

Background:

The Probable ATP-dependent RNA helicase DDX60, also known as DEAD box protein 60, plays a pivotal role in the body's defense against viral infections. It enhances the RIGI- and IFIH1/MDA5-mediated type I interferon and interferon-inducible gene expression. DDX60's ability to bind ssRNA, dsRNA, and dsDNA, and to facilitate RIGI's binding to dsRNA, underscores its versatility and critical function in antiviral responses. It exhibits potent antiviral activity against pathogens like hepatitis C virus and vesicular stomatitis virus (VSV).

Therapeutic significance:

Understanding the role of Probable ATP-dependent RNA helicase DDX60 could open doors to potential therapeutic strategies.